What question did this study set out to answer?

The aim is to evaluate the effectiveness of BB-031 in reducing NETs and inflammatory markers in acute ischemic stroke models.

February 2, 2026Stroke

Abstract DP316: BB-031 inhibition of VWF in AIS: does it cast a large NETs?

View Full Paper

Ask AI

Bookmark

Authors

Animal model demonstrates BB-031 reduces inflammatory markers in acute ischemic stroke, suggesting new therapeutic approaches.

The aim is to evaluate the effectiveness of BB-031 in reducing NETs and inflammatory markers in acute ischemic stroke models.
Administered BB-031 in varying doses post-eMCAO in canines.
Analyzed inflammatory markers including VWF, CitH3, MPO, and NE post-treatment.
Conducted statistical analysis to compare treatment effects against vehicle.
BB-031 significantly reduced VWF levels compared to vehicle across all doses.
Both 1.0 mg/kg and 5.0 mg/kg BB-031 decreased CitH3 levels compared to vehicle.
5.0 mg/kg BB-031 showed lower MPO and NE levels, significantly different from vehicle results.

Anderson et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark